Literature DB >> 31822015

Natural history of acromegaly: Incidences, re-operations, cancers, and mortality rates in a national cohort.

Jau-Ching Wu, Wen-Cheng Huang, Hsuan-Kan Chang, Chin-Chu Ko, Jiing-Feng Lirng, Yu-Chun Chen.   

Abstract

BACKGROUND: Acromegaly is so rare that its natural history, including incidence, risk of cancers, and mortality rates remain elusive. This natural study utilized a nationwide database to provide a better understanding of acromegaly's disease course.
METHODS: A cohort of 1,195 acromegaly patients were identified and followed-up from 1997 to 2013. Incidence, operation, and re-operation rates were calculated. Excessive mortality and cancer risk related to acromegaly were estimated by standardized mortality ratio (SMR) and standardized incidence ratio (SIR).
RESULTS: The incidence was 2.78 per million-person-years, with little gender predominance (female vs male, 49.5% vs 50.5%, respectively). There was female predominance only among 50 and 60 year olds (incidence rate ratio: 1.37 and 1.43, p<0.001 and p=0.002). Among them, 673 (56.3%) had hypophysectomy surgery, and the young-onset (<40 years) patients had more re-operations (15.5%, p=0.01). The overall mortality rate was 22.3 per 1,000-person-years, with a median survival of 4.67 years (with no gender differences, p=0.38). The overall SMR of acromegaly patients was 1.41 and the onset-age-specific SMRs of the early- and middle-onset patients were higher than for those with late-onset. There were 87 newly-diagnosed cancers in the cohort, with an incidence rate of 10.6 per 1,000-person-years (median: 5.4 years). The overall SIR of cancers was 1.91, and there were no differences among gender, onset-age, and disease duration (all SIR>1, approximately 2).
CONCLUSION: Acromegaly is associated with an excessive risk of mortality and two-fold higher risk of cancers. Patients with acromegaly should be managed appropriately after the diagnosis.
© 2019 S. Karger AG, Basel.

Entities:  

Year:  2019        PMID: 31822015     DOI: 10.1159/000505332

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  4 in total

1.  Changes in olfactory function and olfactory bulb after treatment for acromegaly.

Authors:  Nazan Degirmenci; Hasan Bektas; Erol Senturk; Muzaffer Ilhan; Alev Gunaldi; Esra Ummuhan Mermi Yetis; Sabri Baki Eren
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-01-02       Impact factor: 2.503

2.  Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study.

Authors:  Xiaopeng Guo; Kailu Wang; Siyue Yu; Lu Gao; Zihao Wang; Huijuan Zhu; Bing Xing; Shuyang Zhang; Dong Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-01       Impact factor: 5.555

3.  A Pituitary Society update to acromegaly management guidelines.

Authors:  Maria Fleseriu; Beverly M K Biller; Pamela U Freda; Monica R Gadelha; Andrea Giustina; Laurence Katznelson; Mark E Molitch; Susan L Samson; Christian J Strasburger; A J van der Lely; Shlomo Melmed
Journal:  Pituitary       Date:  2020-10-20       Impact factor: 4.107

4.  Apigenin Improves Hypertension and Cardiac Hypertrophy Through Modulating NADPH Oxidase-Dependent ROS Generation and Cytokines in Hypothalamic Paraventricular Nucleus.

Authors:  Hong-Li Gao; Xiao-Jing Yu; Han-Bo Hu; Qian-Wen Yang; Kai-Li Liu; Yan-Mei Chen; Yan Zhang; Dong-Dong Zhang; Hua Tian; Guo-Qing Zhu; Jie Qi; Yu-Ming Kang
Journal:  Cardiovasc Toxicol       Date:  2021-06-02       Impact factor: 3.231

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.